SMC
Lowered price wins NICE approval for Janssen leukaemia treatment
November 25, 2016Medical Communications, Sales and Marketing Janssen, NICE, SMC, chronic lymphocytic leukaemia, ibrutinib, imbruvica
After being knocked back in the beginning of June this year, NICE has announced that Janssen’s Imbruvica (ibrutinib) will now …
SMC reverses decision on Opdivo in advanced skin cancer
August 8, 2016Manufacturing and Production, Research and Development SMC, Scottish Medicines Consortium, melanoma, opdivo, skin cancer
The Scottish Medicines Consortium (SMC) has reversed an earlier decision for Bristol-Myers Squibb’s Opdivo (nivolumab) and has now approved recommended …
SMC recommends treatment for potentially fatal chemotherapy-related disease
June 16, 2016Research and Development, Sales and Marketing Menarini, SMC, adneuric
The Scottish Medicines Consortium has recommended Adenuric (febuxostat), a treatment for a severe complication that can affect chemotherapy patients in …
Scottish Medicines Consortium does not back Vertex’ cystic fibrosis drugs Orkambi, Kalydeco
May 10, 2016Manufacturing and Production, Research and Development Kalydeco, Orkambi, SMC, Vertex Pharma, cystic fibrosis, regulation
The Scottish Medicines Consortium did not back two cystic fibrosis therapies from Vertex Pharmaceutical (Nasdaq: VRTX). SMC did not recommend …
BMS criticises Scottish regulator over Opdivo skin cancer ‘no’
March 7, 2016Medical Communications, Research and Development Bristol-Myers Sqibb, NICE, SMC, melanoma, opdivo
Bristol-Myers Squibb says the Scottish Medicines Consortium’s (SMC) decision not to recommend its immunotherapy Opdivo (nivolumab) as a monotherapy for …
SMC approves first ever treatment for genetic kidney disease
January 12, 2016Sales and Marketing Otsuka, SMC, Scottish Medicines Consortium, jinarc, kidney disease, tolvaptan
The Scottish Medicines Consortium (SMC) has approved Otsuka’s Jinarc for the treatment of the genetic kidney disease autosomal dominant polycystic …
Cancer and MS drugs approved in Scotland
December 9, 2015Sales and Marketing Celgene, Copaxone, Novartis, SMC, Scottish Medicines Consortium, Tevaq, ceritinib, glatiramer acetate, lenalidomide, lung cancer, multiple myeloma, multiple sclerosis, revlimis, zykadia
The Scottish Medicines Consortium (SMC) has approved three new treatments for lung cancer, multiple sclerosis and multiple myeloma, from Novartis, …
Blow for Scottish women as SMC rejects Afinitor for advanced breast cancer
October 12, 2015Sales and Marketing SMC, advanced breast cancer
The Scottish Medicines Consortium (SMC) has announced that it will not recommend Novartis’s Afinitor (everolimus) for use in advanced breast …
NICE rejects Otelza but SMC recommends it
June 11, 2015Sales and Marketing Astellas, Celgene, NHS, NICE, SMC, Xtandi, otezla
Draft guidance issued by NICE has seen rejections for products including Celgene’s Otelza and Astellas Pharma’s Xtandi, and a call …
Scottish Medicines Consortium approves seven drugs
May 12, 2015Sales and Marketing NHS, SMC, Scottish Medicines Consortium
The Scottish Medicines Consortium has accepted seven new medicines and indications for use on the NHS in Scotland. Two of …
Scottish reforms proven to work says SMC
March 4, 2015Sales and Marketing NHS, NICE, Onglyza, PACE, SMC, Scotland, anne lee, scottish
The chief pharma advisor for the Scottish Medicines Consortium Anne Lee says changes to its processes have contributed to improved …
AstraZeneca diabetes drug approved for use in Scotland
November 11, 2014Sales and Marketing Afinitor, AstraZeneca, Eylea, Onglyza, Perjeta, SMC, diabetes, type 2
The Scottish Medicines Consortium (SMC) has shown AstraZeneca’s Onglyza (saxagliptin) the green light to be used with insulin in patients …
Scottish Medicines Consortium disappoints Celgene
July 8, 2014Sales and Marketing Celgene, SMC, Scottish Medicines Consortium, imnovid, myeloma
Celgene admitted it is ‘disappointed’ with the Scottish Medicines Consortium decision not to recommend blood cancer therapy Imnovid for patients …
NICE rejection looms for Sovaldi
June 16, 2014Sales and Marketing Gilead, NHS, NICE, SMC, hep C, sofosbuvir, sovaldi
In a draft recommendation published today NICE is asking Gilead for more information on its new hepatitis C pill Sovaldi …
Sovaldi hurdles first drug pricing barrier
June 10, 2014Sales and Marketing Gilead, SMC, Scotland, hep C, sofosbuvir, sovaldi
Scotland’s NHS will pay for Gilead’s new hepatitis C pill Sovaldi despite rising concern over its high cost. The Scottish …
Latest content
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board
